As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.

On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...

The wearable cardiac monitor maker VitalConnect has raised $100 million in new capital to aid in the development of its ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette ...

BioMed X Institute is teaming up with the Barbados government in an effort to accelerate cardiometabolic treatments for ...

CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendscho, Ph.D., confirmed with Fierce Biotech. | ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Sonya Stokes, M.D., an emergency room physician in the San Francisco Bay Area, braces herself for a daily deluge of patients ...